215 related articles for article (PubMed ID: 15160318)
1. Resolution of refractory chemotherapy-induced diarrhea (CID) with octreotide long-acting formulation in cancer patients: 11 case studies.
Rosenoff S
Support Care Cancer; 2004 Aug; 12(8):561-70. PubMed ID: 15160318
[TBL] [Abstract][Full Text] [Related]
2. Octreotide LAR resolves severe chemotherapy-induced diarrhoea (CID) and allows continuation of full-dose therapy.
Rosenoff SH
Eur J Cancer Care (Engl); 2004 Sep; 13(4):380-3. PubMed ID: 15305907
[TBL] [Abstract][Full Text] [Related]
3. Octreotide long-acting formulation (LAR) in chronic loperamide-refractory diarrhea not related to cancer treatment.
Mystakidou K; Katsouda E; Tsilika E; Smyrniotis V; Vassiliou I; Tsiatas M; Vlahos L
Anticancer Res; 2006; 26(3B):2325-8. PubMed ID: 16821610
[TBL] [Abstract][Full Text] [Related]
4. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome.
Rubin J; Ajani J; Schirmer W; Venook AP; Bukowski R; Pommier R; Saltz L; Dandona P; Anthony L
J Clin Oncol; 1999 Feb; 17(2):600-6. PubMed ID: 10080605
[TBL] [Abstract][Full Text] [Related]
5. Randomized phase III trial exploring the use of long-acting release octreotide in the prevention of chemotherapy-induced diarrhea in patients with colorectal cancer: the LARCID trial.
Hoff PM; Saragiotto DF; Barrios CH; del Giglio A; Coutinho AK; Andrade AC; Dutra C; Forones NM; Correa M; Portella Mdo S; Passos VQ; Chinen RN; van Eyll B
J Clin Oncol; 2014 Apr; 32(10):1006-11. PubMed ID: 24516038
[TBL] [Abstract][Full Text] [Related]
6. Octreotide in the management of chemoradiotherapy-induced diarrhea refractory to loperamide in patients with rectal carcinoma.
Topkan E; Karaoglu A
Oncology; 2006; 71(5-6):354-60. PubMed ID: 17873499
[TBL] [Abstract][Full Text] [Related]
7. A multicenter, randomized trial of long-acting octreotide for the optimum prevention of chemotherapy-induced diarrhea: results of the STOP trial.
Rosenoff SH; Gabrail NY; Conklin R; Hohneker JA; Berg WJ; Warsi G; Maloney J; Benedetto JJ; Miles EA; Zhu W; Anthony L
J Support Oncol; 2006 Jun; 4(6):289-94. PubMed ID: 16805331
[TBL] [Abstract][Full Text] [Related]
8. Octreotide in chemotherapy induced diarrhoea in colorectal cancer: a review article.
Bhattacharya S; Vijayasekar C; Worlding J; Mathew G
Acta Gastroenterol Belg; 2009; 72(3):289-95. PubMed ID: 19902860
[TBL] [Abstract][Full Text] [Related]
9. Long-acting octreotide in the treatment of diarrhea after pelvic pouch surgery.
Gullichsen R
Tech Coloproctol; 2006 Dec; 10(4):346-9. PubMed ID: 17115310
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of the long-acting octreotide formulation (octreotide-LAR) in patients with thyrotropin-secreting pituitary adenomas.
Caron P; Arlot S; Bauters C; Chanson P; Kuhn JM; Pugeat M; Marechaud R; Teutsch C; Vidal E; Sassano P
J Clin Endocrinol Metab; 2001 Jun; 86(6):2849-53. PubMed ID: 11397898
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of long-acting release octreotide for preventing chemotherapy-induced diarrhoea: protocol for a systematic review.
Deng C; Deng B; Jia L; Tan H
BMJ Open; 2017 Jun; 7(6):e014916. PubMed ID: 28637728
[TBL] [Abstract][Full Text] [Related]
12. Subcutaneous octreotide versus oral loperamide in the treatment of diarrhea following chemotherapy.
Gebbia V; Carreca I; Testa A; Valenza R; Curto G; Cannata G; Borsellino N; Latteri MA; Cipolla C; Florena M
Anticancer Drugs; 1993 Aug; 4(4):443-5. PubMed ID: 8400346
[TBL] [Abstract][Full Text] [Related]
13. Recommended guidelines for the treatment of chemotherapy-induced diarrhea.
Wadler S; Benson AB; Engelking C; Catalano R; Field M; Kornblau SM; Mitchell E; Rubin J; Trotta P; Vokes E
J Clin Oncol; 1998 Sep; 16(9):3169-78. PubMed ID: 9738589
[TBL] [Abstract][Full Text] [Related]
14. Octreotide in the treatment of severe chemotherapy-induced diarrhea.
Zidan J; Haim N; Beny A; Stein M; Gez E; Kuten A
Ann Oncol; 2001 Feb; 12(2):227-9. PubMed ID: 11300329
[TBL] [Abstract][Full Text] [Related]
15. Successful use of long-acting octreotide for intractable chronic gastrointestinal bleeding in children.
O'Meara M; Cicalese MP; Bordugo A; Ambrosi A; Hadzic N; Mieli-Vergani G
J Pediatr Gastroenterol Nutr; 2015 Jan; 60(1):48-53. PubMed ID: 25162361
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic response to octreotide in patients with refractory CPT-11 induced diarrhea.
Pro B; Lozano R; Ajani JA
Invest New Drugs; 2001; 19(4):341-3. PubMed ID: 11561696
[TBL] [Abstract][Full Text] [Related]
17. Octreotide acetate in prevention of chemoradiation-induced diarrhea in anorectal cancer: randomized RTOG trial 0315.
Zachariah B; Gwede CK; James J; Ajani J; Chin LJ; Donath D; Rosenthal SA; Kane BL; Rotman M; Berk L; Kachnic LA
J Natl Cancer Inst; 2010 Apr; 102(8):547-56. PubMed ID: 20339140
[TBL] [Abstract][Full Text] [Related]
18. Association of dose escalation of octreotide long-acting release on clinical symptoms and tumor markers and response among patients with neuroendocrine tumors.
Al-Efraij K; Aljama MA; Kennecke HF
Cancer Med; 2015 Jun; 4(6):864-70. PubMed ID: 25727756
[TBL] [Abstract][Full Text] [Related]
19. Systematic dose-extension of octreotide LAR: the importance of individual tailoring of treatment in patients with acromegaly.
Turner HE; Thornton-Jones VA; Wass JA
Clin Endocrinol (Oxf); 2004 Aug; 61(2):224-31. PubMed ID: 15272918
[TBL] [Abstract][Full Text] [Related]
20. Octreotide therapy of large-volume refractory AIDS-associated diarrhea: a randomized controlled trial.
Garcia Compean D; Ramos Jimenez J; Guzman de la Garza F; Saenz C; Maldonado H; Barragan RF; Michel H
AIDS; 1994 Nov; 8(11):1563-7. PubMed ID: 7848592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
